Abstract
Mast cells (MCs) were first described by Paul Ehrlich as well fed granular cells that stain metachromatically. Today MCs are regarded as multifunctional, granulated, tissue-dwelling cells distributed in the perivascular spaces and connective tissues of every major organ of the body. Their long recognized phenotypic diversity might be associated not only with their anatomic distribution and mediator repertoire, but also with their functional characteristics related to the regulation of effector pathways. In addition to their historical involvement in type I hypersensitivity response, MCs have emerged as versatile effector cells with functional diversity and homeostatic functions in non-IgE-mediated inflammatory responses, autoimmunity, bidirectional interactions with the neuroendocrine circuit, the urinary, gastrointestinal, cardiovascular and endocrine systems, in metabolism and malignancy. Thus, MCs appear to receive, integrate and transmit a wide range of signals in their microenvironment, coordinated by the differential release of their pro-inflammatory and anti-inflammatory granular mediators. Understanding the heterogeneity of this complex cellular communication may provide a tool for selective pharmacological intervention directed to specific MC subsets.
Keywords: Allergy, heterogeneity, homeostasis, inflammation, immunity, mast cell, neuroendocrine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights
Volume: 5 Issue: 4
Author(s): S. Kakavas, E. Zampeli, K. Papamichael, B. Delitheos and E. Tiligada
Affiliation:
Keywords: Allergy, heterogeneity, homeostasis, inflammation, immunity, mast cell, neuroendocrine
Abstract: Mast cells (MCs) were first described by Paul Ehrlich as well fed granular cells that stain metachromatically. Today MCs are regarded as multifunctional, granulated, tissue-dwelling cells distributed in the perivascular spaces and connective tissues of every major organ of the body. Their long recognized phenotypic diversity might be associated not only with their anatomic distribution and mediator repertoire, but also with their functional characteristics related to the regulation of effector pathways. In addition to their historical involvement in type I hypersensitivity response, MCs have emerged as versatile effector cells with functional diversity and homeostatic functions in non-IgE-mediated inflammatory responses, autoimmunity, bidirectional interactions with the neuroendocrine circuit, the urinary, gastrointestinal, cardiovascular and endocrine systems, in metabolism and malignancy. Thus, MCs appear to receive, integrate and transmit a wide range of signals in their microenvironment, coordinated by the differential release of their pro-inflammatory and anti-inflammatory granular mediators. Understanding the heterogeneity of this complex cellular communication may provide a tool for selective pharmacological intervention directed to specific MC subsets.
Export Options
About this article
Cite this article as:
Kakavas S., Zampeli E., Papamichael K., Delitheos B. and Tiligada E., The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2006; 5 (4) . https://dx.doi.org/10.2174/187152306778772793
DOI https://dx.doi.org/10.2174/187152306778772793 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Biomarkers Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
Current Topics in Medicinal Chemistry A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form
Current Pharmaceutical Analysis Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Heat Shock Proteins (HSPs) Based Anti-Cancer Vaccines
Current Molecular Medicine Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Current Medicinal Chemistry Molecular Characterization of Primary and Metastatic Colon Cancer Cells to Identify Therapeutic Targets with Natural Compounds
Current Topics in Medicinal Chemistry The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Revisiting Non-Cancer Drugs for Cancer Therapy
Current Topics in Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer
Current Drug Delivery Editorial
Current Radiopharmaceuticals A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Current Gene Therapy Composition Analysis of <i>Salsola grandis</i> and Its Effects on Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics Congenital Abdominal Aortic Aneurysm: Presentation, Etiology, Diagnosis and Management
New Emirates Medical Journal Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets